Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Poster - [In-Person Posters Mon] Drug Development: Human
  • Poster
  • Oral Valiltramiprosate Shows Sustained CDR-SB Benefit Over 2.5 Years In APOE4/4 MCI Subjects: APOLLOE4 Phase 3 Long-term Extension Results [Board No. Monday-0123]
  • Board no. Monday-0123
    Set Timezone

Susan Abushakra, MD1, Aidan Power, MD1, Susan Flint1, Earvin Liang1, David Watson2, Emer MacSweeney, BSc (Hons), MRCP, FRCR3, Sharon Cohen4, Anton P. Porsteinsson5, Marwan N. Sabbagh, MD6, Patrick Kesslak, PhD1, John A. Hey, PhD1, Margaret Bray1, Adem Albayrak1, Martin Tolar, MD PHD1;
1Alzheon, Framingham, MA, USA, 2Alzheimer’s Research and Treatment Center, Wellington, FL, USA, 3ReCognition Health, London, United Kingdom, 4Toronto Memory Program, Toronto, ON, Canada, 5University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, 6Barrow Neurological Institute, Neurology, Phoenix, AZ, USA
Types
Main Session